CAR iNKT cells targeting tumor antigens such as CD19, CD38, BCMA, CSPG4, and GD2 have been generated, and the efficacy has been evaluated in preclinical models or clinical trials.186, 187, 188, 189. The gene discussed is CD19; the disease is neoplasm.